- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03787628
Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder
This research aims to determine the effects and safety of cannabidiol (CBD) (ATL5 softgel capsules) as an adjunctive therapy for patients, who have Opioid Use Disorder and are taking buprenorphine + naloxone or methadone. Buprenorphine + naloxone and methadone is an approved treatment for Opioid Use Disorder, but relapse to opioid misuse is common among patients who receive this treatment. Finding an adjunctive treatment that reduces relapse for these patients would be helpful.
We will recruit participants from the Tarzana Treatment Center (TTC) in the San Fernando Valley. They will be receiving buprenorphine + naloxone or methadone as part of residential therapy. Potential participants who pass initial screening and wish to continue in the study will provide written, informed consent and will complete a 2-day evaluation, including blood and urine tests, questionnaires about their mood, medical, psychiatric and drug use history and physical exam.
Up to 60 participants who meet all eligibility criteria will be invited to complete baseline assessments (blood and urine tests, questionnaires), and will be assigned randomly to receive CBD (600mg/day) or placebo, corresponding to two groups of up to 30 participants each.
After the baseline measurements, participants will take part in a 28-day treatment phase for 4 weeks. They will take the study medication under supervision (CBD 300 mg twice daily or placebo). Questionnaires on opioid craving, withdrawal, and mood symptoms will be administered daily during the treatment period excluding weekends. After the 28-day intervention, participants will complete the questionnaires and undergo urine drug tests in 4 weekly follow-up visits.
The study will last ~10 weeks, comprising three periods: a screening period (2-weeks when participants are stabilized on buprenorphine + naloxone or methadone in residential treatment at the Tarzana Treatment Center), a treatment period (4 weeks when study CBD or placebo is administered at Tarzana Treatment Center), and a follow-up period (4 weeks after termination of the test intervention).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a randomized, double-blind, placebo controlled, study of Cannabidiol (CBD) (600mg/day) as an adjunctive therapy to buprenorphine + naloxone or methadone in patients who have Opioid Use Disorder and are receiving residential behavioral therapy, including cognitive behavioral therapy. The primary endpoint will be safety and tolerability of CBD in these patients, and it will be assessed via measurement of cardiovascular parameters (heart rate, blood pressure, and cardiac rhythm and conduction on EKG), other vital signs, liver enzymes, pulse oximetry, adverse events, and pharmacokinetics. Secondary measures will include cue-induced craving, reductions in spontaneous craving, opioid withdrawal, negative affective states, and relapse, as well as retention in treatment with buprenorphine + naloxone or methadone.
Patients will be recruited from the Tarzana Treatment Center (TTC) in the San Fernando Valley, where buprenorphine + naloxone or methadone (as part of their treatment) and CBD (as part of this protocol) will be administered. Tarzana Treatment Centers, Inc. is a community-based, private non-profit behavioral healthcare organization located in Southern California with several agency sites, including the one in the San Fernando Valley, where this protocol will be conducted. TTC delivers drug and alcohol use treatment, has been accredited by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) since 1987, and has a workforce that includes physicians, psychologists, and nurses. TTC's substance use treatment approach includes residential programs that are overseen by a Program Director and are staffed by a clinical supervisor, operations supervisor, counselors, interns, nursing staff and 24/7 technicians. Groups and services include education group, process group, 12-step, family group, mental health services and recreation skills. Cognitive-behavioral treatment is used in both individual and group therapy to address craving and relapse issues and in the treatment of mental health problems.
Up to 60 participants who meet all eligibility criteria will be invited to complete baseline assessments (blood and urine tests, questionnaires), and will be assigned randomly to receive CBD or placebo, corresponding of two cohorts of up to 30 participants each. Within each cohort, participants will be randomized by baseline buprenorphine plasma level (either below or ≥ 2 ng/ml).
The study will comprise three periods: a multi (~7-14)-day screening period while participants are stabilized on buprenorphine + naloxone), a 4-week treatment period when study medication will be administered, and a 4-week follow-up period after termination of treatment with medication. Cue-induced craving sessions will be conducted at three times: Day 0 (baseline), Day 7(when a steady state of CBD should have been reached; half-life of CBD after oral administration is 18-32 h),and Day 28 (end of treatment).
Adherence to medication in the trial will be assured as the participant will take the test medication (CBD or placebo) under supervision daily. Blood samples will be collected to determine plasma concentrations of CBD, buprenorphine and its metabolites as well as the endocannabinoids anandamide and 2-AG, which may contribute to the response to CBD, and laboratory assessments of safety. Retention in treatment (this trial plus buprenorphine +naloxone or methadone) will be assessed over the 28-day medication (CBD or placebo) period and weekly follow-up assessments for the subsequent month (28-day follow-up period).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Edythe London, PhD
- Phone Number: 3108250606
- Email: ELondon@mednet.ucla.edu
Study Locations
-
-
California
-
Tarzana, California, United States, 91356
- Recruiting
- Tarzana Treatment Centers
-
Contact:
- Kenneth Bachrach, Ph.D.
- Email: kbachrach@tarzanatc.org
-
Contact:
- Stan Galperson, Psy.D.
- Email: sgalperson@tarzanatc.org
-
Principal Investigator:
- Edythe London, Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ability to read and speak English and has provided written informed consent.
- Age of 18-65 years (inclusive).
- Meeting criteria for an OUD according to the MINI for ≥ 3 months before screening.
- Self-report of opioid use in the 60 days before screening; verified by treatment center records.
- On a stable dose of ≥12 mg buprenorphine, either alone, or in combination with naloxone (buprenorphine/naloxone ratio of 4/1) for at least 7 days prior to starting and for the duration of the treatment phase of the study. OR, receiving methadone maintenance therapy for at least 7 days prior to starting and for the duration of the treatment phase of the study.
- If female, being surgically sterile or willing to use birth control (e.g., oral contraceptives, condoms, intrauterine device) or willingness to abstain from sex throughout the study.
- Body Mass Index (BMI) between 17.5 and 35 kg/m2; total body weight > 110 lb (50 kg).
- Currently in residential treatment at the Tarzana Treatment Center.
Exclusion Criteria:
- History of sensitivity to a CBD product or any of the ingredients in the study drug, including glycerin or gelatin.
- A condition that may affect drug absorption (e.g., gastrectomy).
- Taking a medications that has clinically significant interactions with CBD or are contraindicated for the study (check with study physician).
- Positive urine test for THC at screening.
- Self-report of using CBD at screening.
- PK analysis at screening showing evidence of CBD use (a signal that is ≥ three times the background noise at the corresponding CBD retention time and MS2 transition).
- Physiological dependence on alcohol or a sedative-hypnotic benzodiazepine drug.
- Current medication-assisted treatment with naltrexone.
- Acute opioid withdrawal symptoms, as defined by a score on the COWS > 4.
- Clinical laboratory finding of AST or ALT > 3 times the upper limit of normal (ULN) or bilirubin > 1.5 times ULN.
- AIDS or HIV positive status (because treatment medications have potential interactions with CBD).
- Pregnancy or lactation.
- Clinically significant EKG abnormalities, as determined by the study physician, including the following: QTc >450 msec (men) or >470 (women) or QRS interval >120 msec (If QTc or QRS interval exceed these cutoff points, EKG will be repeated twice and the average of the three QTc values used to determine eligibility.), congenital long QT syndrome, history of prolonged QT in the 3 months before screening, corrected QT interval (Fridericia's - QTcF) >450 msec (male) or >470 msec (female) or history of risk factors for Torsades de Pointes.
- For women: any value outside reference ranges on a hormonal battery [estradiol, follicle-stimulating hormone, free thyroxine index, luteinizing hormone, prolactin, T3 uptake, thyroid-stimulating hormone, and thyroxine], followed by an abnormal ovarian ultrasound finding.
- Clinically significant cardiovascular, hematologic, hepatic, renal, or endocrine abnormalities, as determined by the study physician.
- Meeting criteria on the MINI for schizophrenia, Bipolar I disorder, psychotic disorder, having active suicidal ideation, or suicide attempt in the past 12 months. Or, answers "yes" to questions 4 or 5 on C-SSRS. NOTE: Participants with other psychiatric conditions, such as major depression, generalized anxiety, dysthymia, social phobia or specific phobia may be enrolled in the study if they are clinically stable.
- On the cue-induced opiate craving task at screening, the participant does not have a score of at least 25 (on a visual analogue scale with a maximum score of 100) for at least one image within one category. Note: Groups of images may be separated into smoking cues, pills and bottles, and injection paraphernalia. For example, for injection cues, a picture of a needle and syringe may elicit a craving response, though other images in the same group (i.e., picture of arm with vein bulging) do not elicit craving.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cannabidiol (CBD) 600 mg
Thirty participants who meet all eligibility criteria will be randomized to receive CBD (ATL5; Ananda Scientific) at a dose of 600 mg.
|
CBD (300 mg) will be administered orally twice daily in the morning and again in the afternoon.
The active ingredient in the Ananda investigational new drug, ATL5, is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml od CBD per capsule).
The novel formulation is based on the principle that a water-free mixture of some concentrated inactive ingredients (excipients) self-assemble spontaneously into liquid nanodomains that contain the active component CBD.
ATL5 Softgel Capsules will be manufactured by Baxco Pharmaceutical Inc., (California, USA) under cGMP conditions.
|
Placebo Comparator: Placebo
Thirty participants who meet all eligibility criteria will be randomized to receive placebo.
|
The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules.
This formulation will be manufactured by Baxco Pharmaceutical Inc under cGMP conditions.
Different amounts (numbers of softgel capsules) of placebo will be administered to match that of the active compound, daily in the morning and afternoon for each of 28 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary endpoint will be safety and tolerability of CBD
Time Frame: Days 1-56
|
Safety will be assessed via measurement of cardiovascular parameters (heart rate, blood pressure, and cardiac rhythm and conduction on EKG), other vital signs, liver enzymes, pulse oximetry, and adverse events.
|
Days 1-56
|
Safety will also be assessed via measurement of plasma levels of buprenorphine and metabolites (norbuprenorphine and buprenorphine glucuronide).
Time Frame: Before dosing (day 0) and during the treatment (days 3,7,14,21 and 28) and during the follow-up period (days 35,42,49 and 56).
|
Investigators will evaluate whether CBD might pose potential safety concerns associated with buprenorphine treatment.
This study will seek to understand the drug-drug interaction for safe and effective treatment of Opioid Use Disorder and to identify an optimal adjunctive dose of CBD for patients receiving buprenorphine + naloxone treatment.
Investigators predict a drug-drug interaction between CBD and buprenorphine, in which CBD will dose-dependently inhibit buprenorphine metabolism and therefore increase the ratio of buprenorphine/norbuprenorphine concentrations.
|
Before dosing (day 0) and during the treatment (days 3,7,14,21 and 28) and during the follow-up period (days 35,42,49 and 56).
|
Safety will also be assessed via measurement of plasma levels of anandamide and 2 AG.
Time Frame: Before dosing (day 0) and during the treatment (days 3,7,14,21 and 28) and during the follow-up period (days 35,42,49 and 56).
|
Because CBD is an inhibitor of fatty acid amide hydrolase (FAAH), the principal enzyme catalyzing the catabolism of the major endocannabinoids (N-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG), administration of CBD may affect plasma concentrations of these endocannabinoids.
Plasma levels of anandamide and 2-AG will be determined in order to obtain preliminary data on the extent to which CBD effects on the primary endpoints in the study reflect actions to increase anandamide and 2-AG concentrations.
It is predicted that high baseline endocannabinoids will be associated with a smaller overall CBD effect and/or a maximum CBD effect at a lower dose.
|
Before dosing (day 0) and during the treatment (days 3,7,14,21 and 28) and during the follow-up period (days 35,42,49 and 56).
|
Safety will also be assessed via measurement of plasma levels of CBD as well as its metabolites 7-hydoxy-CBD and 7-carboxy-CBD.
Time Frame: Before dosing (day 0) and during the treatment (days 3,7,14,21 and 28) and during the follow-up period (days 35,42,49 and 56).
|
Plasma concentrations of CBD and its metabolites will be used to determine the pharmacokinetic (PK) parameters using noncompartmental PK analysis.
|
Before dosing (day 0) and during the treatment (days 3,7,14,21 and 28) and during the follow-up period (days 35,42,49 and 56).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The extent to which CBD reduces cue-induced craving for opioids
Time Frame: During the laboratory session before dosing on Day 0 (baseline without CBD) and on Days 7 and 28 after adjunctive treatment with CBD.
|
Patients will be presented with 90 images, which consist of 40 heroin-related, 40 prescription-opioid-related and 10 neutral pictures.
After the presentation of each cue, patients will rate their opioid craving by responding to 7 items derived from the Desire for Drug Questionnaire (DDQ).Each item is measured on a 7-point Likert scale, so that the craving score may range from 7 to 49.
The primary outcome will be quantified as the change in craving response in the context of opioid cue-induced craving from the laboratory session before dosing on Day 0 (baseline without CBD) to Days 7 and 28 (after adjunctive treatment with CBD).
|
During the laboratory session before dosing on Day 0 (baseline without CBD) and on Days 7 and 28 after adjunctive treatment with CBD.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Spontaneous opioid craving using the Penn Alcohol-Craving Scale adapted for opioid
Time Frame: At baseline before dosing(Day 0), daily during treatment period(28 days), and weekly during follow-up period (up to 4 weeks).
|
A brief (5-item) unidimensional measure of craving.
Items assess craving retrospectively during the week before testing.
Responses can range from 0 to 6, and the scale is defined as the mean item score.Higher scores show higher levels of craving.
|
At baseline before dosing(Day 0), daily during treatment period(28 days), and weekly during follow-up period (up to 4 weeks).
|
Spielberger State-Trait Anxiety Inventory
Time Frame: At baseline before dosing(Day 0), daily during treatment period(28 days), and weekly during follow-up period (up to 4 weeks).
|
A 40-item self-report rating scale for assessing anxiety.
It comprises two subscales (each 20 items): the State Anxiety subscale evaluates how respondents feel "right now" and the Trait Anxiety subscale measures a generalized propensity to be anxious.
All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always").
Higher scores indicate greater anxiety.
|
At baseline before dosing(Day 0), daily during treatment period(28 days), and weekly during follow-up period (up to 4 weeks).
|
Positive and Negative Affect Schedule (PANAS)
Time Frame: At baseline before dosing(Day 0), daily during treatment period(28 days), and weekly during follow-up period (up to 4 weeks).
|
Affect is assessed using this 20-item questionnaire that measures both positive and negative affect.
Each item is rated on a 5-point scale ranging from 1 (very slightly or not at all).
|
At baseline before dosing(Day 0), daily during treatment period(28 days), and weekly during follow-up period (up to 4 weeks).
|
Percentage of patients who relapse during the trial
Time Frame: Throughout the study period
|
The percentage of individuals who relapse to opioid use during the trial will be determined via self-report and biochemical confirmation obtained by daily urine drug testing.
|
Throughout the study period
|
Treatment retention
Time Frame: Throughout the study period
|
Treatment retention as indicated by number of days of continued participation
|
Throughout the study period
|
Collaborators and Investigators
Investigators
- Principal Investigator: Edythe London, PhD, University of California, Los Angeles
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-001748
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid-use Disorder
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorder | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorders | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Vanderbilt University Medical CenterCompletedOpioid Use | Opioid-use DisorderUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Albert Einstein College of MedicineNational Institute on Drug Abuse (NIDA); Pfizer; National Institutes of Health...Active, not recruitingTobacco Use Disorder | Opioid-use DisorderUnited States
-
Indiana UniversityCompletedOpioid Use | Opioid-use DisorderUnited States
-
University of ZurichCompletedOpioid Use, Unspecified With Other Opioid-induced DisorderSwitzerland
-
Virginia Commonwealth UniversityNational Institute on Drug Abuse (NIDA)CompletedOpioid-use Disorder | Cocaine Use Disorder | Healthy Controls | Marijuana Use DisorderUnited States
-
New York State Psychiatric InstituteColumbia University; Weill Medical College of Cornell University; National Institute... and other collaboratorsActive, not recruitingOpioid Use | Opioid Court Model | Medication to Treat Opioid Use DisorderUnited States
Clinical Trials on Cannabidiol (CBD) 600 mg
-
Bod AustraliaWoolcock Institute of Medical ResearchCompletedInsomnia | Sleep Disturbance | Insomnia Type; Sleep Disorder | Insomnia, Transient | Insomnia Due to Anxiety and Fear | Insomnia Due to Other Mental DisorderAustralia
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)RecruitingTobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco DependenceUnited States
-
University of California, Los AngelesNot yet recruitingTobacco Smoking | Tobacco Use Disorder | Tobacco DependenceUnited States
-
Zealand University HospitalUniversity of CopenhagenActive, not recruitingChemotherapy-induced Peripheral NeuropathyDenmark
-
Colorado State UniversityCompletedPharmacokinetics | Metabolism | Liver FunctionUnited States
-
West Virginia UniversityCompletedCognitive Impairment | Mood | Sedation Complication | Driving PerformanceUnited States
-
National Institute on Drug Abuse (NIDA)Completed
-
University of NebraskaUniversity of Texas at Austin; Ananda Scientific IncRecruiting
-
University of Northern ColoradoCompleted
-
Pure GreenCompletedMusculoskeletal PainUnited States